News and Events

Programs and providers of Obstetrics and Gynecology at Weill Cornell Medicine are often the focus of news stories and features appearing in major national media. We invite you to review some stories that typify the breakthrough accomplishments of our remarkable team and highlight the impact our care has had on patient’s lives.

Diet, Microbes and Fat: A New Pathway Controlling Levels of Body Fat and Cholesterol

pink fat droplets in liver tissue with a chemical structure superimposed on it

Beneficial gut microbes and the body work together to fine-tune fat metabolism and cholesterol levels, according to a new preclinical study by investigators from Weill Cornell Medicine and the Boyce Thompson Institute at Cornell University’s Ithaca campus.

The human body has co-evolved with the beneficial microbes that live in the gut (termed the microbiota), resulting in mutually favorable relationships that aid in the digestion of food and absorption of essential nutrients required for survival of the host and the gut microbes. A central aspect of these relationships is the production of bioactive molecules that promote the breakdown of food, enabling nutrient absorption by the host. One of the most important groups of such molecules are termed bile acids (also known as ‘bile’) which are produced from cholesterol in the liver and then delivered to the intestine where they promote fat digestion.

Scientists have known for some time that gut bacteria modify bile acids into a form that stimulates a receptor called FXR, which reduces bile production. The new study, published Jan. 8 in Nature, reveals that an enzyme produced by intestinal cells converts bile acids into a different form that has the opposite effect. This altered form, called bile acid-methylcysteamine (BA–MCY), inhibits FXR to promote bile production and help boost fat metabolism.

Weill Cornell Anesthesiologist Selected for 2024 HHMI Hanna H. Gray Fellowship

A man posing for a photo with the 59th street bridge in the background

Dr. Jim Castellanos (M.D. ’20, Ph.D. ’18), an instructor in anesthesiology at Weill Cornell Medicine, has been selected as a 2024 Hanna H. Gray Fellow by the Howard Hughes Medical Institute (HHMI).

Dr. Castellanos is one of 25 early-career scientists in the United States selected this year for this prestigious program, which aims to recruit and retain scientists from gender, racial, ethnic and other groups underrepresented in the life sciences. Hanna H. Gray Fellows receive up to $1.5 million over the span of eight years, providing funds for the remainder of their postdoctoral training and also during their early years as independent faculty. In addition to financial support, the program also includes professional development, mentoring opportunities and active involvement in the HHMI community.

“I finished my clinical residency a few months ago and now I want to tackle a big, important scientific question,” said Dr. Castellanos, who is an anesthesiology fellow at Weill Cornell Medicine and a postdoctoral fellow in Dr. Elaine Fuchs’ lab at The Rockefeller University. “It’s validating that HHMI believes in the importance of my project and are investing in my development as a physician-scientist.”

GLP-1 Drugs May Reduce Surgery Complications in Patients with Diabetes

image of doctors performing surgery

People with diabetes who were taking GLP-1 receptor agonist drugs such as tirzepatide and semaglutide had significantly lower rates of hospital readmission, wound re-opening and hematoma after surgery, according to a large study led by investigators at Weill Cornell Medicine, Columbia University Vagelos College of Physicians and Surgeons and NewYork-Presbyterian.

The study, published online in advance of print on Dec. 20 in the Annals of Surgery, analyzed de-identified hospital records covering 74,425 surgical procedures in 21,772 patients with diabetes over a three-and-a-half-year period ending in July 2023. The investigators found that patients taking GLP-1 receptor agonists, known informally as GLP-1 drugs, had about a 12% lower risk of hospital readmission within a month of surgery, a 29% lower risk of wound re-opening within six months of surgery, and about a 56% lower risk of hematoma (a collection of blood in tissue caused by bleeding) at the surgery site, compared with patients who were not taking such medications.